Novalex Therapeutics

Novalex Therapeutics is leveraging preclinical biology research to develop an enzyme inhibitor. The fatty acid biosynthesis pathway, known as enoyl reductase or FabI, is being targeted for the development of novel potential drugs to treat Staphylococcus aureus and its drug-resistant strain, MRSA.